Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10513530 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Patent 10513530 was granted and assigned to Karus Therapeutics on December, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Karus Therapeutics

Current Assignee

Karus Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

105135300

Patent Inventor Names

Stephen Joseph Shuttleworth0

Alexander Richard Liam Cecil0

Franck Alexandre Silva0

Date of Patent

December 24, 2019

Patent Application Number

159614040

Date Filed

April 24, 2018

Patent Citations

‌

US Patent 10035785 Phosphoinositide 3-kinase inhibitors

‌

US Patent 10087179 Fused tricyclic imidazole derivatives as modulators of TNF activity

Patent Citations Received

‌

US Patent 11779586 Compounds comprising tricyclic heterocyclic compounds

‌

US Patent 10870624 Histone deacetylase inhibitors

‌

US Patent 11708378 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Patent Primary Examiner

‌

Rebecca L Anderson

Patent abstract

A compound of formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10513530 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API